Abstract：Objective: To research the effect of intraperitoneal perfusion in patients with ovarian cancer and its effect on serum fibroblast growth factor(Bfgf), Humanepididymisprotein4(HE4) and alpha fetoprotein(AFP). Methods:According to the treatment methods, 90 patients with ovarian cancer admitted to our hospital from March 2014 to March 2015 were divided into experimental group and control group, 45 cases in each group. Both groups were given hydration (intravenous drip of 20 mL potassium chloride + 1000 mL normal saline), diuresis, antiemetic, etc., and tumor cell reduction surgery. On this basis, the control group was treated with neoadjuvant chemotherapy. The experimental group was treated with neoadjuvant chemotherapy and intraperitoneal perfusion before operation, and continued to be treated with TP after operation. Each cycle was 28 days, and the treatment course of the two groups was 6-8 cycles. The operation indexes (operation time, intraoperative bleeding volume, ascites volume), serum bFGF, HE4, AFP levels, adverse reactions and therapeutic effect were compared between the two groups. Results: The operation time, the amount of blood loss and the volume of ascites in the experimental group were significantly lower than those in the control group[(136.08±17.35)min vs(160.26±20.64)min,(540.21±121.36)mL vs(610.36±134.08)mL,(510.32±113.65)mL vs(917.87±132.48)mL](P<0.05); The levels of bFGF, HE4 and AFP were significantly lower than those of the control group[(65.90±9.36)ng/L vs(96.34±12.75)ng/L,(42.69±8.17)pmol/L vs(75.38±13.49)pmol/L,(5.83±1.02)ng/mL vs(13.97±3.57)ng/mL](P<0.05); The total incidence of adverse reactions was significantly lower than that of the control group [20.00%(9/45)vs 46.66%(21/45)](P<0.05); Total remission rate was significantly higher than that of the control group [91.11%(41/45)vs 71.11%(32/45)](P<0.05). Conclusion: The application of intraperitoneal perfusion in patients with ovarian cancer has a significant effect, which can effectively improve the clinical symptoms of patients, reduce the level of serum bFGF, HE4, AFP, promote the apoptosis of tumor cells, inhibit the formation of blood vessels, reduce toxic and side effects, and improve the prognosis.
余少康, 靳枫, 李柱, 潘毅贞, 王树滨, 邱莉. 腹腔灌注在卵巢癌患者中的临床疗效及对血清bFGF HE4 AFP的影响[J]. 河北医学, 2019, 25(12): 1965-1969.
YU Shaokang, JIN Feng, LI Zhu, et al. Effect of Intraperitoneal Perfusion in Patients with Ovarian Cancer and its Effect on Serum bFGF HE4 and AFP. HeBei Med, 2019, 25(12): 1965-1969.
[1] Lee KC, Lin H, Chang Chien CC,et al. Difficulty in diagnosis and different prognoses between colorectal cancer with ovarian metastasis and advanced ovarian cancer: An empirical study of different surgical adoptions[J]. Taiwan Obstet Gynecol,2017,56(1):62~67. [2] Sun Y, Tao W, Huang M, et al. Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome[J].Cell Mol Med,2017,21(3):510~518. [3] 杨利娟,张波,杨永秀.新辅助化疗与初始肿瘤细胞减灭术治疗晚期卵巢癌疗效的系统评价[J].中国实用妇科与产科杂志,2017,33(2):171~176. [4] 谭文福,张帆.腹腔灌注联合静脉化疗治疗晚期卵巢癌疗效观察[J].武汉大学学报(医学版),2015,36(1):66~68,128. [5] Tanyi JL, Stashwick C, Plesa G, et al. Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells[J].Immunother,2017,40(3):104~107. [6] Mittapalli RK, Nuthalapati S, Shepherd SP, et al. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer[J]. Cancer Chemother Pharmacol,2017;79(3):587~594. [7] Cousin S, Grellety T, Toulmonde M, et al. Clinical impact of extensive molecular profiling in advanced cancer patients[J].Hematol Oncol,2017,10(1):45. [8] Zou L, Wang D, Hu Y, et al. Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles[J]. Oncotarget,2017,8(36):60453~60468. [9] 李正红,郭科军,温放,等.新辅助化疗治疗晚期卵巢癌的临床疗效评价[J].中国医科大学学报,2012,41(7):645~649. [10] Monk BJ. Optimal treatment for platinum-sensitive recurrent ovarian cancer[J]. Clin Adv Hematol Oncol,2017,15(9):674~676. [11] Wang H, Zheng J, Li Q, et al. Expression of the tumor suppressor gene p16, and lymph node metastasis in patients with ovarian cancer[J]. Oncol Lett,2017,14(4):4689~4693. [12] Li S, Li H, Xu Y, et al. Identification of candidate biomarkers for epithelial ovarian cancer metastasis using microarray data[J]. Oncol Lett,2017,14(4):3967~3974.
2019, Vol. 25 
冀公网安备13080202000786号